Positive Outcome of Phase I DNA Influenza Study
OXFORD, England -- PowderMed Ltd. (PowderMed), a company focusing on the development of therapeutic DNA vaccines, has announced positive results in a Phase I clinical trial of a proprietary prophylactic DNA influenza vaccine.
The trial examined three doses of the DNA influenza vaccine (one, two and four micrograms), in 12 volunteers per arm, making 36 volunteers in total. Each was administered as a single dose to healthy adult volunteers. The immune response was assessed according to the criteria laid down by the Committee for Proprietary Medicinal Products (CPMP) for the approval of annual flu vaccines in the European Union. All three doses passed the CPMP criteria at 56 days and the maximum dose (four micrograms) passed the criteria at 21 days and was well tolerated. At the maximum dose (four micrograms) 100 percent of the subjects achieved a seroprotective level of antibodies demonstrating that this DNA vaccine is a viable candidate for further trials to develop a vaccine against influenza or pandemic flu.
Dr. Clive Dix, CEO of PowderMed commented: "We are very encouraged by this positive clinical data generated with PowderMed technology. I am convinced that a PowderMed DNA flu vaccine could become a viable solution for the current threat from pandemic flu."
This DNA influenza vaccine can be readily commercialized using PowderMed's proprietary PowderJect(TM) Particle Mediated Epidermal Delivery (PMED(TM)) technology. DNA vaccines using PMED are highly versatile in that they rely on powdered DNA and can be stored at room temperature and have much longer shelf-lives than traditional vaccines.
Source: PowderMed Ltd.
How Contaminated Is Your Stretcher? The Hidden Risks on Hospital Wheels
July 3rd 2025Despite routine disinfection, hospital surfaces, such as stretchers, remain reservoirs for harmful microbes, according to several recent studies. From high-touch areas to damaged mattresses and the effectiveness of antimicrobial coatings, researchers continue to uncover persistent risks in environmental hygiene, highlighting the critical need for innovative, continuous disinfection strategies in health care settings.
Beyond the Surface: Rethinking Environmental Hygiene Validation at Exchange25
June 30th 2025Environmental hygiene is about more than just shiny surfaces. At Exchange25, infection prevention experts urged the field to look deeper, rethink blame, and validate cleaning efforts across the entire care environment, not just EVS tasks.
A Controversial Reboot: New Vaccine Panel Faces Scrutiny, Support, and Sharp Divides
June 26th 2025As the newly appointed Advisory Committee on Immunization Practices (ACIP) met for the first time under sweeping changes by HHS Secretary Robert F. Kennedy Jr, the national spotlight turned to the panel’s legitimacy, vaccine guidance, and whether science or ideology would steer public health policy in a polarized era.
